Compare Adaptive Biotechnologies Corp (ADPT) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs First Trust Cloud Computing ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while First Trust Cloud Computing ETF trades at $138.07. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, First Trust Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SKYY | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $155.17 |
52-Week Low | $10.24 | $104.16 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SKYY, the First Trust Cloud Computing ETF, trades at $139.01, up 3.08% today, with a bullish technical signal from moving averages but mixed oscillators. The ETF provides diversified exposure to the cloud computing sector, which is benefiting from enterprise digital transformation and AI adoption. Recent news highlights strong inflows into technology ETFs and the launch of AI tools to aid investment decisions.
The outlook for SKYY is positive, driven by sustained demand for cloud services and AI integration, though risks include sector volatility and competitive pressures. Investors should monitor earnings growth of underlying holdings and broader tech sector trends for continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
